PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 120 | 2 | 275-281
Article title

Breast cancer and factors affecting survival rate. Narrative review article

Content
Title variants
Languages of publication
EN
Abstracts
EN
Breast cancer is the most common malignancy in women and it was estimated as the fifth cause of death from malignancy in the world. The objective of this review is to illustrate the incidence of cancer breast and demonstrate different factors affecting survival rate.
Discipline
Year
Volume
120
Issue
2
Pages
275-281
Physical description
Contributors
  • Department of Anesthesia, ICU and Pain Relief, South Egypt Cancer Institute, Assiut University, Arab Republic of Egypt
  • Department of Biochemistry, Faculty of Medicine, Assiut University, Arab Republic of Egypt
  • Department of Anesthesia, ICU and Pain Relief, South Egypt Cancer Institute, Assiut University, Arab Republic of Egypt
References
  • [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018; 68 (6): 394-424
  • [2] Duffy MJ. Predictive markers in breast and other cancers: a review. Clinical chemistry 2005; 51 (3): 494-503
  • [3] Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. The Lancet 2005; 365 (9453): 60-62
  • [4] Olefsky JM. Nuclear receptor minireview series-Introduction. Journal of Biological Chemistry 2001 Oct 5; 276 (40): 36863-4
  • [5] Gilcrease M. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Breast Diseases: A Year Book Quarterly 2010; 4 (21): 336-7
  • [6] Savouret J, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A, et al. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. The EMBO Journal 1991; 10 (7): 1875-83
  • [7] Russnes HG, Lingjaerde OC, Børresen-Dale A-L, Caldas C. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. The American journal of pathology 2017; 187 (10): 2152-62
  • [8] Group EBCTC. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet 2011; 378 (9793): 771-84
  • [9] Munoz D, Near AM, Van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. JNCI: Journal of the National Cancer Institute 2014; 106 (11)
  • [10] Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences 2001; 98 (19): 10869-74
  • [11] Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. Journal of clinical oncology 2008; 26 (7): 1059-65
  • [12] Ren Z, Li Y, Shen T, Hameed O, Siegal GP, Wei S. Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis. Pathology - Research and Practice 2016; 212 (1): 24-30
  • [13] Hill DA, Barry M, Wiggins C, Nibbe A, Royce M, Prossnitz E, et al. Estrogen receptor quantitative measures and breast cancer survival. Breast cancer research and treatment 2017; 166 (3): 855-64
  • [14] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO Journal 2000; 19 (13): 3159-67
  • [15] Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. The Oncologist 2009; 14 (4): 320-68
  • [16] Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. Journal of clinical oncology 2010; 28 (1): 92
  • [17] Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine 2011; 365 (14): 1273-83
  • [18] Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine 2012; 367(19): 1783-91
  • [19] Tao L, Chu L, Wang LI, Moy L, Brammer M, Song C, et al. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes & Control 2016; 27(9): 1127-38
  • [20] Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. New England Journal of Medicine 1993; 328(22): 1587-91
  • [21] Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology 1996; 14 (10): 2702-8
  • [22] Ozdogan M, Samur M, Bozcuk HS, Sagtas E, Yildiz M, Artac M, et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Japanese journal of clinical oncology 2003; 33 (5): 229-31
  • [23] Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Journal of clinical oncology 2009; 27(34): 5693-9
  • [24] Stuart-Harris R, Shadbolt B, Palmqvist C, Ross HC. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors. The Breast 2009; 18 (6): 351-5
  • [25] Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, et al. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Annals of Oncology 2017; 28 (1): 16-33
  • [26] Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. Journal of Clinical Oncology 2012; 30 (6): 593
  • [27] Tobin N, Harrell J, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of Oncology 2014; 26 (1): 81-8
Document Type
short_communication
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-3f325068-8448-4c2f-9923-8fc20416bc3d
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.